PureTech Health - drug delivery

The Monash Institute of Pharmaceutical Sciences (MIPS) has licensed a lymphatic drug targeting technology platform to the clinical-stage biopharmaceutical company PureTech Health plc. This novel technology was developed by Professor Chris Porter’s group at the ARC Centre of Excellence for Bio-Nano Science and Technology (the CBNS) at MIPS. The technology will be progressed towards clinical trial by PureTech Health through a new subsidiary start-up, Glyph Biosciences, in collaboration with Dr Porter’s laboratory.

Named “Glyph”, the platform is aimed at harnessing the biology of the lymphatic system to develop novel therapeutics. It holds promise for the development of new medicines that are both more potent and less toxic to the liver, and have the potential to pave the way for new treatments for a range of conditions, from cancer to autoimmune disease.

PureTech Health’s growing research and development pipeline has been developed in collaboration with some of the world’s leading scientific experts, to advance opportunities that hold the most promise for patients.

See news story.

PureTech announced the start of Phase 1 clinical trials in December 2021: https://news.puretechhealth.com/node/10051/pdf